<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185468</url>
  </required_header>
  <id_info>
    <org_study_id>GIMI-IRB-17004</org_study_id>
    <nct_id>NCT03185468</nct_id>
  </id_info>
  <brief_title>Intervention of Bladder Cancer by CAR-T</brief_title>
  <official_title>Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Geno-Immune Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II and multicenter study designed to evaluate the efficacy and safety of&#xD;
      4SCAR-T cells in participants with locally advanced or metastatic urothelial bladder cancer&#xD;
      (UBC) who have no further treatment available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival rate after receiving 4SCART infusion</measure>
    <time_frame>1 year</time_frame>
    <description>to determine the efficacy of 4SCAR T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Using CTCAE 4 standard to evaluate the level of adverse events after receiving 4SCART infusion</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate the level of adverse events with CTCAE 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The expansion and persistence of 4SCAR T cells</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators will monitor the expansion and functional persistence of 4SCAR T cells in the peripheral blood of patients and the correlation with antitumor effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune responses after infusions</measure>
    <time_frame>3 months</time_frame>
    <description>assessment of cytokine profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urothelial Carcinoma Bladder</condition>
  <arm_group>
    <arm_group_label>4SCAR-PSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4SCAR-FRa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>4SCAR-PSMA</intervention_name>
    <description>PSMA-specific 4th Generation CART</description>
    <arm_group_label>4SCAR-PSMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>4SCAR-FRa</intervention_name>
    <description>FRa-specific 4th Generation CART</description>
    <arm_group_label>4SCAR-FRa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically documented locally advanced or metastatic UBC&#xD;
             (including renal pelvis, ureters, urinary bladder, and urethra)&#xD;
&#xD;
          2. Representative tumor specimens as specified by the protocol&#xD;
&#xD;
          3. Adequate hematologic and end organ function&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          5. Life expectancy greater than or equal to (&gt;/=) 12 weeks&#xD;
&#xD;
          6. Measurable disease, as defined by RECIST v1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment&#xD;
&#xD;
          2. Treatment with any other investigational agent or participation in another clinical&#xD;
             trial with therapeutic intent within 28 days prior to enrollment&#xD;
&#xD;
          3. Active or untreated central nervous system (CNS) metastases as determined by computed&#xD;
             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and&#xD;
             prior radiographic assessments&#xD;
&#xD;
          4. Leptomeningeal disease&#xD;
&#xD;
          5. Malignancies other than UBC within 5 years prior to Cycle 1, Day 1&#xD;
&#xD;
          6. Pregnant and lactating women&#xD;
&#xD;
          7. Significant cardiovascular disease&#xD;
&#xD;
          8. Severe infections within 4 weeks prior to infusion&#xD;
&#xD;
          9. Major surgical procedure other than for diagnosis within 4 weeks&#xD;
&#xD;
         10. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy&#xD;
             to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the&#xD;
             atezolizumab formulation&#xD;
&#xD;
         11. History of autoimmune disease&#xD;
&#xD;
         12. Prior allogeneic stem cell or solid organ transplant&#xD;
&#xD;
         13. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest CT scan&#xD;
&#xD;
         14. Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or&#xD;
             hepatitis C or tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Geno-Immune Medical Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <phone>86-13671121909</phone>
    <email>c@szgimi.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aifa Tang, PhD</last_name>
    <email>tangaifa2004@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenzhen Second People Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Gongdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AiFa Tang, Ph. D</last_name>
      <email>tangaifa2004@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Geno-immune Medical Institute</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lung-Ji Chang, PhD</last_name>
      <phone>86-13671121909</phone>
      <email>c@szgimi.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Geno-Immune Medical Institute</investigator_affiliation>
    <investigator_full_name>Lung-Ji Chang</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

